Mixed
Combined treatment with dapagliflozin (10 mg/day) and n-3 carboxylic acids (4 g/day) significantly reduces liver fat content (PDFF) in individuals with type 2 diabetes and NAFLD, achieving a greater reduction than either monotherapy.
For individuals with Type 2 Diabetes and fatty liver, combining a standard dose of dapagliflozin (10 mg daily) with a high dose of omega-3 carboxylic acids (4 g daily) for 12 weeks significantly reduces liver fat content more effectively than using either treatment alone. This dual approach leverages both energy balance and fatty acid metabolism pathways to improve liver health.
Combined treatment with dapagliflozin and OM-3CA significantly reduced liver fat content... The combination treatment (relative change, −21%, adjusted p < 0.05), but not dapagliflozin (−13%) or OM-3CA (−15%) as monotherapies, significantly lowered liver PDFF compared with placebo (−3%).
Why this rating
Double-blind, randomised, placebo-controlled trial with adequate power, though limited to 12 weeks and a specific diabetic population.
Source
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
Jan W. Eriksson et al. · Diabetologia · 2018
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →